Bay Street News

Certara Launches Phoenix™ Version 8.5 Drug Development Software

RADNOR, Pa., Aug. 15, 2024 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Phoenix™ version 8.5. Phoenix is the pharmaceutical industry’s gold standard in pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic modeling and simulation software. The Phoenix Platform is used by more than 75 of the top 100 pharmaceutical companies worldwide. Eleven regulatory agencies, including the U.S. FDA, Japan PMDA, and China NMPA, rely on Phoenix to evaluate life-saving drug candidates. Version 8.5 is the latest release from Certara’s Phoenix Platform, available as a hosted solution for maximum performance and lower total cost of ownership.

Today, 88% of new medicines that enter clinical trials fail, indicating a need for improved processes. Certara’s Phoenix platform expedites everything from data preparation to report generation – a time-consuming process that drug developers rely on.

“Certara develops software solutions that transform research data into trustworthy insights for scientists and regulators with the goal of bringing new medicines to market faster,” said Max Kanevsky, Chief Technology Officer at Certara. “The latest version of Phoenix includes new capabilities requested by existing clients and their IT business partners that streamline the comprehensive PK/PD data workflow.”

Version 8.5 delivers new features driven by customer demand. These features improve the efficiency, quality, and speed of PK/PD workflows within Phoenix.

Developed with feedback from clients that participate in the Phoenix customer advisory board and user group communities, Phoenix 8.5 will improve users’ access and experience, allowing for more effective analysis, interpretation, and visualization of data. To learn more, visit https://www.certara.com/software/phoenix-pkpd/.

About Certara

Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. Its clients include more than 2,400 biopharmaceutical companies, academic institutions, and regulatory agencies across 66 countries. Learn more at certara.com.

Certara Contact: 
Sheila Rocchio 
sheila.rocchio@certara.com  

Media Contact: 

Alyssa Horowitz 
certara@pancomm.com


Bay Street News